Copanlisib: First Global Approval

2018-07-26T21:31:45Z (GMT) by Anthony Markham
<h5>Compliance with Ethical Standards</h5><h5><i>Funding </i>The preparation of this review was not supported by any external funding.</h5><h5><i>Conflicts of interest </i>A. Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.</h5><h5>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.<br></h5><div><b>Abstract</b></div><div>Bayer are developing copanlisib (Aliqopa™) – a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor – as a treatment for various haematological and solid malignancies. The US FDA has granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments based on the results of a phase II trial. Phase III trials are underway evaluating copanlisib as treatment for relapsed/refractory diffuse large B-cell lymphoma and in combination with rituximab or rituximab-based chemotherapy or standard immunochemotherapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. Phase I/II studies are underway in relapsed or refractory peripheral T-cell or NK/T-cell lymphoma, advanced cholangiocarcinoma, hormone receptor-positive HER2-negative stage I-IV breast cancer, HER2-positive breast cancer and recurrent and/or metastatic head and neck squamous cell carcinomas harbouring a PI3KCA mutation/amplification and/or a PTEN loss. This article summarizes the milestones in the development of copanlisib leading to this first approval for relapsed follicular lymphoma.<br></div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017<br></div><div><br></div>

Categories

License

CC BY-NC 4.0